Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Tamaki N, et al. Among authors: hasebe c. Invest New Drugs. 2022 Dec;40(6):1290-1297. doi: 10.1007/s10637-022-01303-w. Epub 2022 Sep 24. Invest New Drugs. 2022. PMID: 36152108
Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group.
Joko K, Goto T, Watanabe H, Mitsuda A, Uchida Y, Hasebe C, Tsuruta S, Kimura H, Koike T, Akamatsu T, Mashiba T, Ochi H, Nakamura Y, Tsuchiya K, Kurosaki M, Izumi N. Joko K, et al. Among authors: hasebe c. Hepatol Res. 2016 Apr;46(4):251-8. doi: 10.1111/hepr.12515. Epub 2015 Mar 24. Hepatol Res. 2016. PMID: 25753220
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
Itakura J, Kurosaki M, Hasebe C, Osaki Y, Joko K, Yagisawa H, Sakita S, Okushin H, Satou T, Hisai H, Abe T, Tsuji K, Tamada T, Kobashi H, Mitsuda A, Ide Y, Ogawa C, Tsuruta S, Takaguchi K, Murakawa M, Asahina Y, Enomoto N, Izumi N. Itakura J, et al. Among authors: hasebe c. PLoS One. 2016 Oct 24;11(10):e0165339. doi: 10.1371/journal.pone.0165339. eCollection 2016. PLoS One. 2016. PMID: 27776192 Free PMC article.
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis.
Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Fujii H, et al. Among authors: hasebe c. Hepatol Res. 2018 Aug;48(9):746-756. doi: 10.1111/hepr.13070. Epub 2018 May 17. Hepatol Res. 2018. PMID: 29480939
Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, Izumi N. Tsuji K, et al. Among authors: hasebe c. J Gastroenterol. 2018 Oct;53(10):1142-1150. doi: 10.1007/s00535-018-1455-1. Epub 2018 Apr 6. J Gastroenterol. 2018. PMID: 29626296
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
Suda G, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. Among authors: hasebe c. J Gastroenterol. 2019 Jan;54(1):78-86. doi: 10.1007/s00535-018-1495-6. Epub 2018 Jul 17. J Gastroenterol. 2019. PMID: 30019127
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, Nasu A, Ogawa C, Kojima Y, Hasebe C, Wada S, Uchida Y, Sohda T, Suzuki H, Yoshida H, Kusakabe A, Tamada T, Kobashi H, Mitsuda A, Kondo M, Shigeno M, Ide Y, Morita A, Kitamura T, Abe T, Izumi N. Akahane T, et al. Among authors: hasebe c. Hepatol Res. 2019 Mar;49(3):264-270. doi: 10.1111/hepr.13246. Epub 2018 Oct 20. Hepatol Res. 2019. PMID: 30171740
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. Among authors: hasebe c. J Gastroenterol. 2019 Jul;54(7):641-649. doi: 10.1007/s00535-019-01556-y. Epub 2019 Feb 18. J Gastroenterol. 2019. PMID: 30778716
48 results